FLT3 pathway is a potential therapeutic target for PRC2-mutated T-cell acute lymphoblastic leukemia

Blood. 2018 Dec 6;132(23):2520-2524. doi: 10.1182/blood-2018-04-845628. Epub 2018 Oct 3.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Female
  • Humans
  • Male
  • Mutation*
  • Polycomb Repressive Complex 2 / genetics*
  • Polycomb Repressive Complex 2 / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Signal Transduction / genetics*
  • fms-Like Tyrosine Kinase 3 / genetics*
  • fms-Like Tyrosine Kinase 3 / metabolism

Substances

  • Polycomb Repressive Complex 2
  • FLT3 protein, human
  • fms-Like Tyrosine Kinase 3